Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
A Phase Ib Study of Cediranib in Combination With Cilengitide in Patients With Recurrent Glioblastoma
Sponsor: National Cancer Institute (NCI)
Listed as NCT00979862, this PHASE1 trial focuses on Adult Giant Cell Glioblastoma and Adult Glioblastoma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Mar 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .